니코틴 껌 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Nicotine Gum Market Summary

The global nicotine gum market size was estimated at USD 1.50 billion in 2025 and is projected to reach USD 2.48 billion by 2033, growing at a CAGR of 6.7% from 2026 to 2033. The demand for nicotine replacement therapy (NRT) products, including nicotine gum, has been increasing globally in recent years as more people are opting for methods to quit smoking and reduce their exposure to the harmful chemicals found in tobacco smoke.

Some of the latest trends in the global NRT market include the development of more convenient and effective NRT products, such as long-lasting gums, and the growing popularity of flavored options. In addition, there has been an increase in the number of people using NRT products to quit smoking, as well as a rise in the number of healthcare professionals recommending NRT products to their patients.

Nicotine gum sales are rising mainly because more smokers are trying to quit (or cut down) and they increasingly want convenient, discreet, non-prescription options they can use at work, while traveling, or alongside coaching/apps. Gum is also benefiting from stricter tobacco-control policies (higher taxes, smoke-free spaces, plain packaging, advertising limits) that keep nudging smokers toward cessation aids, plus wider OTC availability and e-commerce that make it easier to buy and repurchase without a clinic visit.

Consumers increasingly combine behavioral support with nicotine replacement therapies (NRTs), or use NRTs such as nicotine gum alongside gradual reduction strategies instead of abrupt cessation. Population-level evidence from England indicates that a substantial share of quit attempts now involves pharmacological or nicotine-based aids rather than unassisted "cold turkey" approaches. This shift supports sustained demand for nicotine gum, even as overall cigarette consumption declines, as smokers view gum as a flexible, controllable tool within a broader quitting journey rather than a standalone intervention.

Furthermore, affordability improvements in high-pile, ultra-soft materials, including microfiber, fleece, and faux-fur blends, have enabled deeper household penetration, particularly in emerging consumer clusters in India. Consumers are no longer purchasing blankets solely for warmth, but also for lounging, work-from-home, travel comfort, and gifting.

The market for nicotine gum is expanding steadily as rising health consciousness and stronger public awareness of smoking-related risks encourage more consumers to quit or reduce cigarette consumption. Over the past decade, governments, public health agencies, and non-profit organizations have intensified anti-smoking campaigns highlighting the links between tobacco use and cardiovascular disease, cancer, and respiratory disorders. Policy frameworks such as Healthy People 2030 set explicit objectives to reduce tobacco use and smoking-related illness in the U.S., advocating for evidence-based strategies including smoke-free environments, pricing policies, education campaigns, and access to quitting support and medications. These measures are intended to reduce morbidity and mortality, particularly among high-risk demographic groups. As a result, smoking is increasingly viewed not only as a long-term health risk but also as a barrier to overall wellness and quality of life.

In the U.S., federal and state-level actions have similarly prioritized smoking reduction and cessation support. Federal public health agencies such as the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) provide extensive, publicly available cessation resources through initiatives such as Smokefree.gov and quit lines, including 1-800-QUIT-NOW, alongside behavior change support and counseling services that complement the use of NRT products. These programs aim to address both the physical and behavioral aspects of tobacco dependence, reflecting clinical practice guidelines that recommend combining pharmacotherapy with behavioral interventions.

Product innovation, especially in flavor formats, has further strengthened the appeal of nicotine gum. Historically, unpleasant taste and mouthfeel were major barriers to long-term adherence. In response, manufacturers have introduced a wider range of flavors, including mint variations, fruit profiles, cinnamon, and milder neutral options, alongside sugar-free formulations. These improvements make the product more palatable and reduce early discontinuation, particularly among first-time users. Variety of flavors also allows consumers to personalize their quitting experience, aligning with broader trends toward customization and user comfort in health and wellness products.

Convenience and discreet usage have additionally contributed to market growth. Nicotine gum can be used without drawing social attention, does not produce vapor or odor, and fits easily into daily routines at workplaces or during travel. Combined with expanded availability through pharmacies, supermarkets, and online channels, this convenience lowers barriers to trial and repeat purchase.

Global Nicotine Gum Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segment from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the nicotine gum market on the basis of type, distribution channel, and region.

• Type Outlook (Revenue, USD Million; 2021 - 2033)
• 2mg
• 4mg
• Distribution Channel Outlook (Revenue, USD Million; 2021 - 2033)
• Supermarkets/hypermarkets
• Convenience stores
• Pharmacies
• Online
• Regional Outlook (Revenue, USD Million; 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources & Third-Party Perspectives
  • 1.3.4. Primary Research
• 1.4. Information Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Data Visualization
• 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Type Outlook
• 2.3. Distribution Channel Outlook
• 2.4. Regional Outlook

Chapter 3. Nicotine Gum Market Variables, Trends & Scope

• 3.1. Market Introduction
• 3.2. Penetration and Growth Prospect Mapping
• 3.3. Industry Value Chain Analysis
  • 3.3.1. Raw Material Trends
  • 3.3.2. Sales Channel Analysis
• 3.4. Market Dynamics
  • 3.4.1. Market Driver Analysis
  • 3.4.2. Market Restraint Analysis
  • 3.4.3. Industry Challenges
  • 3.4.4. Industry Opportunities
• 3.5. Business Environment Analysis
  • 3.5.1. Industry Analysis - Porter's
• 3.6. Market Entry Strategies

Chapter 4. Consumer Behavior Analysis

• 4.1. Demographic Analysis
• 4.2. Consumer Trends and Preferences
• 4.3. Factors Affecting Buying Decision
• 4.4. Observations & Recommendations

Chapter 5. Nicotine Gum Market: Type Estimates & Trend Analysis

• 5.1. Nicotine Gum Market, by Type: Key Takeaways
• 5.2. Type Movement Analysis & Market Share, 2025 & 2033
• 5.3. Market Estimates & Forecasts, by Type, 2021 - 2033 (USD Million)
  • 5.3.1. 2mg
    • 5.3.1.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 5.3.2. 4mg
    • 5.3.2.1. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. Nicotine Gum Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Nicotine Gum Market, by Distribution Channel: Key Takeaways
• 6.2. Distribution Channel Movement Analysis & Market Share, 2025 & 2033
• 6.3. Market Estimates & Forecasts, by Distribution Channel, 2021 - 2033 (USD Million)
  • 6.3.1. Supermarkets & Hypermarkets
    • 6.3.1.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3.2. Convenience Stores
    • 6.3.2.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3.3. Pharmacies
    • 6.3.3.1. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 6.3.4. Online
    • 6.3.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Nicotine Gum Market: Regional Estimates & Trend Analysis

• 7.1. Nicotine Gum Market: Regional Outlook
• 7.2. Regional Movement Analysis & Market Share, 2025 & 2033
• 7.3. Market Estimates & Forecasts, by Region & Country, 2021 - 2033 (USD Million)
  • 7.3.1. North America
    • 7.3.1.1. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.1.2. U.S.
      • 7.3.1.2.1. Key country dynamics
      • 7.3.1.2.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.1.3. Canada
      • 7.3.1.3.1. Key country dynamics
      • 7.3.1.3.2. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.2. Europe
    • 7.3.2.1. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.2.2. Germany
      • 7.3.2.2.1. Key country dynamics
      • 7.3.2.2.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.2.3. U.K.
      • 7.3.2.3.1. Key country dynamics
      • 7.3.2.3.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.2.4. France
      • 7.3.2.4.1. Key country dynamics
      • 7.3.2.4.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.2.5. Italy
      • 7.3.2.5.1. Key country dynamics
      • 7.3.2.5.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.2.6. Spain
      • 7.3.2.6.1. Key country dynamics
      • 7.3.2.6.2. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.3. Asia Pacific
    • 7.3.3.1. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3.2. China
      • 7.3.3.2.1. Key country dynamics
      • 7.3.3.2.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3.3. Japan
      • 7.3.3.3.1. Key country dynamics
      • 7.3.3.3.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3.4. India
      • 7.3.3.4.1. Key country dynamics
      • 7.3.3.4.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3.5. Australia & New Zealand
      • 7.3.3.5.1. Key country dynamics
      • 7.3.3.5.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.3.6. South Korea
      • 7.3.3.6.1. Key country dynamics
      • 7.3.3.6.2. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.4. Latin America
    • 7.3.4.1. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.4.2. Brazil
      • 7.3.4.2.1. Key country dynamics
      • 7.3.4.2.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.4.3. Mexico
      • 7.3.4.3.1. Key country dynamics
      • 7.3.4.3.2. Market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.5. Middle East & Africa
    • 7.3.5.1. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.5.2. South Africa
      • 7.3.5.2.1. Key country dynamics
      • 7.3.5.2.2. Market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.3.5.3. UAE
      • 7.3.5.3.1. Key country dynamics
      • 7.3.5.3.2. Market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Competitive Analysis

• 8.1. Recent developments & impact analysis, by key market participants
• 8.2. Company Categorization
• 8.3. Participant's Overview
• 8.4. Financial Performance
• 8.5. Product Benchmarking
• 8.6. Company Market Share Analysis, 2025 (%)
• 8.7. Company Heat Map Analysis
• 8.8. Strategy Mapping
• 8.9. Company Profiles
  • 8.9.1. Johnson & Johnson
    • 8.9.1.1. Company Overview
    • 8.9.1.2. Financial Performance
    • 8.9.1.3. Product Benchmarking
    • 8.9.1.4. Strategic Initiatives
  • 8.9.2. Novartis AG
    • 8.9.2.1. Company Overview
    • 8.9.2.2. Financial Performance
    • 8.9.2.3. Product Benchmarking
    • 8.9.2.4. Strategic Initiatives
  • 8.9.3. ITC Limited
    • 8.9.3.1. Company Overview
    • 8.9.3.2. Financial Performance
    • 8.9.3.3. Product Benchmarking
    • 8.9.3.4. Strategic Initiatives
  • 8.9.4. Cipla Health Limited
    • 8.9.4.1. Company Overview
    • 8.9.4.2. Financial Performance
    • 8.9.4.3. Product Benchmarking
    • 8.9.4.4. Strategic Initiatives
  • 8.9.5. Perrigo Company Plc.
    • 8.9.5.1. Company Overview
    • 8.9.5.2. Financial Performance
    • 8.9.5.3. Product Benchmarking
    • 8.9.5.4. Strategic Initiatives
  • 8.9.6. Teva Canada
    • 8.9.6.1. Company Overview
    • 8.9.6.2. Financial Performance
    • 8.9.6.3. Product Benchmarking
    • 8.9.6.4. Strategic Initiatives
  • 8.9.7. Philip Morris
    • 8.9.7.1. Company Overview
    • 8.9.7.2. Financial Performance
    • 8.9.7.3. Product Benchmarking
    • 8.9.7.4. Strategic Initiatives
  • 8.9.8. British American Tobacco PLC
    • 8.9.8.1. Company Overview
    • 8.9.8.2. Financial Performance
    • 8.9.8.3. Product Benchmarking
    • 8.9.8.4. Strategic Initiatives
  • 8.9.9. Dr. Reddy's Laboratories Ltd
    • 8.9.9.1. Company Overview
    • 8.9.9.2. Financial Performance
    • 8.9.9.3. Product Benchmarking
    • 8.9.9.4. Strategic Initiatives
  • 8.9.10. Pfizer Inc.
    • 8.9.10.1. Company Overview
    • 8.9.10.2. Financial Performance
    • 8.9.10.3. Product Benchmarking
    • 8.9.10.4. Strategic Initiatives